EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Endocrinology: What You May Have Missed in 2024

Mohamed Aman, Athavi Jeevananthan, Maria Martinez-Cruz, Neesha Namasingh, Bryan C Batch

Annals of Internal Medicine · 2025

DOI: 10.7326/annals-25-00990 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Internal Medicine, 2025. Verfasst von Mohamed Aman und 4 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, Ontario, Canada (M.A.). Hauptthemen laut MEDLINE: Endocrinology, Glucagon-Like Peptide-1 Receptor Agonists, Endocrine System Diseases. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During 2024, there were many practice-changing innovations in the field of endocrinology, particularly related to the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs). From the substantial new evidence published in 2024, 10 studies are highlighted that offer critical information for clinicians who manage or comanage patients with endocrine disorders including prediabetes, diabetes, obesity, and hyperparathyroidism. Two of the 10 articles are focused on use of GLP-1RAs in multiple clinical settings not studied in the original GLP-1RA trials, including after bariatric surgery and before endoscopy. Two additional studies focused on GLP-1RA explore the risk for thyroid cancer in patients prescribed GLP-1RA and the effect of a GLP-1RA on chronic kidney disease in patients with type 2 diabetes. Three articles investigate opportunities for deintensification of insulin frequency or an alternate method of insulin delivery in patients with type 2 diabetes. One article explores the cardiometabolic effects of intermittent fasting in persons with prediabetes and type 2 diabetes. The last 2 articles explore the incidence of diabetes after SARS-CoV-2 infection and the skeletal effects of parathyroidectomy as a treatment of hyperparathyroidism. The results of each study have a direct effect on the delivery of care for patients with prediabetes, type 2 diabetes, and hyperparathyroidism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndocrinologyGlucagon-Like Peptide-1 Receptor AgonistsEndocrine System DiseasesHumansCOVID-19Diabetes Mellitus, Type 2Prediabetic StateHyperparathyroidism

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • McMaster University, Hamilton, Ontario, Canada (M.A.).
  • Duke University, Durham, North Carolina (A.J., M.M.-C., N.N., B.C.B.).

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Aman, M., Jeevananthan, A., Martinez-Cruz, M., Namasingh, N., & Batch, B. C. (2025). Endocrinology: What You May Have Missed in 2024. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-00990

Vancouver

Aman M, Jeevananthan A, Martinez-Cruz M, Namasingh N, Batch BC. Endocrinology: What You May Have Missed in 2024. Annals of Internal Medicine. 2025. doi:10.7326/annals-25-00990

BibTeX
@article{Aman2025,
  author = {Aman, Mohamed and Jeevananthan, Athavi and Martinez-Cruz, Maria and Namasingh, Neesha and Batch, Bryan C},
  title = {Endocrinology: What You May Have Missed in 2024},
  journal = {Annals of Internal Medicine},
  year = {2025},
  doi = {10.7326/annals-25-00990}
}
Kostenlos starten →